The renin-angiotensin systems: Evolving pharmacological perspectives for cerebroprotection

Current Pharmaceutical Design

Volumn 11, Issue 25, 2005, Pages 3275-3291

  Magy, Laurent ^a   Vincent, François ^a   Faure, Sebastien ^a   Messerli, Franz H ^b   Wang, Jiguag G ^c   Achard, Jean Michel ^a   Fournier, Albert ^d  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; AMASTATIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN[1-7]; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRILAT; GLUTAMYL AMINOPEPTIDASE; IRBESARTAN; LISINOPRIL; LOSARTAN; MEMBRANE METALLOENDOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; PERINDOPRIL; RAMIPRIL; SARALASIN; UNINDEXED DRUG;

AGING; ANTIHYPERTENSIVE ACTIVITY; ATHEROGENESIS; BLOOD PRESSURE REGULATION; BRAIN ISCHEMIA; BRAIN PROTECTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DOSE RESPONSE; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLEIOTROPY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; SYSTEMATIC REVIEW;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; BRAIN ISCHEMIA; HUMANS; NEUROPROTECTIVE AGENTS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR REMODELING;

EID: 24944523363     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774424726     Document Type: Review

References (145)

1. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16(2): 149-60.
2. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov 2002; 1(8): 621-36.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in High-Risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288(23): 2981-2997.
4. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43(8): 1343-7.
5. Tigerstedt R, Bergman PG. Niere und Kreilauf. Skand Arch Physiol 1898; 8: 223-71.
6. Goldblatt H, Linch J, Hanzal RF, Summerville WW. Studies on experimental hypertension. The production of persistent elevation of systolic blood pressure by means of renal ischaemia. J Exp Med 1934; 59: 347-79.
7. Fasciolo JC. The experimental observation that led to discovery of angiotensin. 1939 Buenos Aires, Argentina. Hypertension 1990; 16: 194-8.
8. Dzau VJ. Vascular wall renin-angiotensin pathway in control of the circulation. A hypothesis. Am J Med 1984; 77(4A): 31-6.
9. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37(4): 1047-52.
10. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci USA 1996; 93(21): 11968-73.
11. Hamilton TA, R.K H, Harding JW, Wright JW. A role for the angiotensin IV/AT4 system in mediating natriuresis in the rat. Peptides 2001; 22(6): 935-44.
12. Coleman J, Krebs L, Hamilton T, Ong B, Lawrence K, Sardinia M, et al. Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats. Peptides 1998; 19(2): 269-77.
13. Kramar EA, Harding JW, Wright JW. Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2 and AT4 receptor subtypes. Regul Pept 1997; 68(2): 131-8.
14. Kramar EA, Krishnan R, Harding JW, Wright JW. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul Pept 1998; 74(2-3): 185-92.
15. Patel J, Martens JR, Li YD, Gelband CH, Raizada MK, Block ER. Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. Am J Physiol. 1998; 275(6 Pt 1): L1061-8.
16. Hill-Kapturczak N, Kapturczak MH, Block ER, Patel JM, Malinski T, Madsen KM, et al. Angiotensin II-stimulated nitric oxide release from porcine pulmonary endothelium is mediated by angiotensin IV. J Am Soc Nephrol. 1999; 10(3): 481-91.
17. Garrison EA, Santiago JA, Osei SY, Kadowitz PJ. Analysis of responses to angiotensin peptides in the hindquarters vascular bed of the cat. Am J Physiol 1995; 268(6 Pt 2): H2418-25.
18. Champion HC, Garrison EA, Estrada LS, Potter JM, Kadowitz PJ. Analysis of responses to angiotensin I and angiotensin I-(3-10) in the mesenteric vascular bed of the cat. Eur J Pharmacol 1996; 309(3): 251-9.
19. Champion HC, Kadowitz PJ. Analysis of the effects of candesartan in the mesenteric vascular bed of the cat. Hypertension 1997; 30(5): 1260-6.
20. Gardiner SM, Kemp PA, March JE, Bennett T. Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol 1993; 110(1): 159-62.
21. Champion HC, Czapla MA, Kadowitz PJ. Responses to angiotensin peptides are mediated by AT1 receptors in the rat. Am J Physiol 1998; 274(1 Pt 1): E115-23.
22. Loufrani L, Henrion D, Chansel D, Ardaillou R, Levy BI. Functional evidence for an angiotensin IV receptor in rat resistance arteries. J Pharmacol Exp Ther 1999; 291(2): 583-8.
23. Lambert DG, Champion HC, Kadowitz PJ. Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat. Can J Physiol Pharmacol 1998; 76(2): 133-40.
24. Nossaman BD, Feng CJ, Kaye AD, Kadowitz PJ. Analysis of responses to ANG IV: effects of PD-123319 and DuP-753 in the pulmonary circulation of the rat. Am J Physiol 1995; 268(2 Pt 1): L302-8.
25. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 1998; 31 (1 Pt 2): 362-7.
26. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52(3): 415-72.
27. Unger T. The angiotensin II type 2 receptor: variations on an enigmatic theme. J Hypertension 1999; 17: 1775-1786.
28. Lo M, Liu KL, Lantelme P, Sassard J. Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest 1995; 95(3): 1394-7.
29. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995; 377(6551): 748-50.
30. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377(6551): 744-7.
31. Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999; 96(11):: 6506-10.
32. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 2003; 42(4): 600-4.
33. Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 1999; 34(5): 1112-6.
34. Gigante B, Piras O, De Paolis P, Porcellini A, Natale A, Volpe M. Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens 1998; 16(12 Pt 2): 2039-43.
35. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31: 349-55.
36. Akishita M, Iwai M, Wu L, Zhang L, Ouchi Y, Dzau VJ, et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodelling after aortic banding in mice. Circulation 2000; 102(14): 1684-9.
37. Ichihara S, Senbonmatsu T, Price E, Jr., Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001; 104(3): 346-51.
38. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T. Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation 2002; 106(17): 2244-9.
39. Li JS, Touyz RM, Schiffrin EL. Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension 1998; 31(1 Pt 2): 487-92.
40. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensinII on the rat vascular structure. J Clin Invest 1996; 15;98(2): 418-25.
41. Sabri A, Levy BI, Poitevin P, Caputo L, Faggin E, Marotte F, et al. Differential roles of AT1 and AT2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II. Arterioscler Thromb Vasc Biol 1997; 17(2): 257-64.
42. De Paolis P, Porcellini A, Gigante B, Giliberti R, Lombardi A, Savoia C, et al. Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells. J Hypertens 1999; 17(12 Pt 2): 1873-7.
43. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96(11): 3954-62.
44. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995; 95(1): 46-54.
45. Viswanathan M, Saavedra JM. Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing. Peptides 1992; 13(4): 783-6.
46. Horiuchi M, Akishita M, Dzau VJ. Molecular and cellular mechanism of angiotensin II-mediated apoptosis. Endocr Res 1998; 24(3-4): 307-14.
47. Horiuchi M, Yamada T, Hayashida W, Dzau VJ. Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis. J Biol Chem 1997; 272(18): 11952-8.
48. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996; 93(1): 156-60.
49. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998; 188(4): 661-70.
50. Herdegen T, Skene P, Bähr M. The C-jun transcription factor - bipotential mediator of neuronal death, survival and regeneration. TINS (Trends Neurosci) 1997; 20: 227-231.
51. Santos A, Campagnole-Santos MJ, Baracho NC, Fontes MA, Silva LC, Neves LA, et al. Characterisation of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 1994; 35(4): 293-8.
52. Jackson TR, Blair LA, Marshall J, Goedert M, Hanley MR. The mas oncogene encodes an angiotensin receptor. Nature 1988; 335(6189): 437-40.
53. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100(14): 8258-63.
54. Ambuhl P, Felix D, Khosla MC. [7-D-ALA]-angiotensin-(1-7): selective antagonism of angiotensin-(1-7) in the rat paraventricular nucleus. Brain Res Bull 1994; 35(4): 289-91.
55. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30(3 Pt 2): 535-41.
56. Tallant EA, Lu X, Weiss RB, Chappell MC, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension 1997; 29(1 Pt 2): 388-93.
57. Neves LA, Averill DB, Ferrario CM, Chappell MC, Aschner JL, Walkup MP, et al. Characterisation of angiotensin-(1-7) receptor subtype in mesenteric arteries. Peptides 2003; 24(3): 455-62.
58. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27(3 Pt 2): 523-8.
59. Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 2003; 284(6): H1985-94.
60. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998; 31(1 Pt 2): 356-61.
61. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31(2): 699-705.
62. Iyer SN, Averill DB, Chappell MC, Yamada K, Allred AJ, Ferrario CM. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension 2000; 36(3): 417-22.
63. Liu L, Ikeda K, Yamori Y. Changes in stroke mortality rates for 1950 to 1997: a great slowdown of decline trend in Japan. Stroke 2001; 32: 1745-9.
64. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1-7): in vivo and in vitro studies. Am J Physiol 1996; 270(1 Pt 2): F141-7.
65. Lara LS, Bica RB, Sena SL, Correa JS, Marques-Fernandes MF, Lopes AG, et al. Angiotensin-(1-7) reverts the stimulatory effect of angiotensin II on the proximal tubule Na(+)-ATPase activity via a A779-sensitive receptor. Regul Pept. 2002; 103(1):: 17-22.
66. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 28(1): 104-07.
67. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33(1 Pt 2): 207-11.
68. Tallant EA, Diz DI, Ferrario CM. State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 1999; 34(4 Pt 2): 950-7.
69. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87(5): E1-9.
70. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417(6891): 822-8.
71. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme related carboxypeptidase. J Biol Chem 2002; 277(17): 14838-43.
72. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136(1-2): 355-60.
73. O'Carroll AM, Selby TL, Palkovits M, Lolait SJ. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta. 2000; 1492(1): 72-80.
74. De Falco M, De Luca L, Onori N, et al. Apelin expression in normal human tissues. In vivo 2002; 16(5: 333-6.
75. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation. 2003; 108(12): 1432-9.
76. Tatemoto K, Takayama K, Zou M, Kumaki I, Zhang W, Kumano K, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001(99(2-3)): 87-92.
77. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002; 91(5): 434-40.
78. Reaux A, Gallatz K, Palkovits M, Llorens-Cortes C. Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience. 2002; 113(3): 653-62.
79. De Mota N, Lenkei Z, Llorens-Cortes C. Cloning, pharmacological characterisation and brain distribution of the rat apelin receptor. Neuroendocrinology 2000; 72(6): 400-7.
80. Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, et al. Physiological role of a novel neuropeptide, apelin and its receptor in the rat brain. J Neurochem. 2001; 77(4): 1085-96.
81. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem. 2001; 276(52): 48623-6.
82. Keller SR, Scott HM, Mastick CC, Aebersold R, Lienhard GE. Cloning and characterisation of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J Biol Chem 1995; 270(40): 23612-8.
83. Rogi T, Tsujimoto M, Nakazato H, Mizutani S, Tomoda Y. Human placental leucine aminopeptidase/oxytocinase. A new member of type II membrane-spanning zinc metallopeptidase family. J Biol Chem 1996; 271(1): 56-61.
84. Keller SR. The insulin-regulated aminopeptidase: a companion and regulator of glut4. Front Biosci 2003; 8: S410-20.
85. Wu-Wong JR, Berg CE, Wang J, Chiou WJ, Fissel B. Endothelin stimulates glucose uptake and GLUT4 translocation via activation of endothelin ETA receptor in 3T3-L1 adipocytes. J Biol Chem. 1999; 274(12): 8103-10.
86. Matsumoto H, Rogi T, Yamashiro K, Kodama S, Tsuruoka N, Hattori A, et al. Characterisation of a recombinant soluble form of human placental leucine aminopeptidase/oxytocinase expressed in Chinese hamster ovary cells. Eur J Biochem. 2000; 267(1): 46-52.
87. Matsumoto H, Nagasaka T, Hattori A, Rogi T, Tsuruoka N, Mizutani S, et al. Expression of placental leucine aminopeptidase/oxytocinase in neuronal cells and its action on neuronal peptides. Eur J Biochem. 2001; 268(11): 3259-66.
88. Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem. 2003; 86(2): 344-50.
89. Thomas WG, Mendelsohn FA. Angiotensin receptors: form and function and distribution. Int J Biochem Cell Biol. 2003; 35(6): 774-9.
90. Llorens-Cortes C, Mendelsohn FA. Organisation and functional role of the brain angiotensin system. J Renin Angiotensin Aldosterone Syst 2002; 3 Suppl 1: S39-48.
91. Rozenfeld R, Reaux A, Iturrioz X, Fassot C, Fournie-Zaluski MC, David C, et al. Aminopeptidase A, generating one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, plays a key role in central control ofblood pressure. Proc West Pharmacol Soc 2003; 46: 39-44.
92. Wright JW, Miller-Wing AV, Shaffer MJ, Higginson C, Wright DE, Hanesworth JM, et al. Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Res Bull. 1993; 32(5): 497-502.
93. Wright JW, Stubley L, Pederson ES, Kramar EA, Hanesworth JM, Harding JW. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 1999; 19(10): 3952-61.
94. Kramar EA, Armstrong DL, Ikeda S, Wayner MJ, Harding JW, Wright JW. The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res 2001; 897(1-2): 114-21.
95. Wright JW, Kramar EA, Myers ED, Davis CJ, Harding JW. Ethanol-induced suppression of LTP can be attenuated with an angiotensin IV analog. Regul Pept 2003; 113(1-3): 49-56.
96. Wright JW, Kramar EA, Meighan SE, Harding JW. Extracellular matrix molecules, long-term potentiation, memory consolidation and the brain angiotensin system. Peptides 2002; 23(1): 221-46.
97. Ferrario CM, Iyer SN. Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. Regul Pept 1998;; 78(1-3): 13-8.
98. Jin XQ, Fukuda N, Su JZ, Lai YM, Suzuki R, Tahira Y, et al. Angiotensin II type 2 receptor gene transfer downregulates angiotensin II type 1a receptor in vascular smooth muscle cells. Hypertension 2002; 39(5): 1021-7.
99. Tschope C, Spillmann F, Altmann C, Koch M, Westermann D, Dhayat N, et al. The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc Res 2004; 61(3): 559-69.
100. Fernandez L, Caride V, Twickler J, Galardy R. Renin-angiotensin and development of collateral circulation after renal ischaemia. Am J Physiol 1982; 243: H869-75.
101. Fernandez L, Spencer D, Kaczmar T. Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation. Stroke 1986; 17: 82-5.
102. Kaliszewski C, Fernandez L, Wicke J. Differences in mortality rate between abrupt and progressive carotid ligation in the gerbil: role of endogenous angiotensin II. J Cerebral Blood Flow and Metab 1988; 8: 149-54.
103. Fernandez LA, Caride VJ, Stromberg C, Naveri L, Wicke JD. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol 1994; 24(6): 937-40.
104. Dalmay F, Mazouz H, Allard J, Pesteil F, Achard JM, Fournier A. Non AT1-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. JRAAS 2001; 2: 103-106.
105. Makino I, Shibata K, Ohgami Y, Fujiwara M, Furukawa T. Transient upregulation of the AT2 receptor mRNA level after global ischaemia in the rat brain. Neuropeptides 1996; 30(6): 596-601.
106. Hoe KL, Armando I, Baiardi G, Sreenath T, Kulkarni A, Martinez A, et al. Molecular cloning, characterisation and distribution of the gerbil angiotensin II AT2 receptor. Am J Physiol Regul Integr Comp Physiol 2003; 285(6): R1373-83.
107. Naveri L, Stromberg C, Saavedra JM. Angiotensin IV reverses the acute cerebral blood flow reduction after experimental subarachnoid hemorrhage in the rat. J Cereb Blood Flow Metab 1994; 14(6): 1096-9.
108. Wu-Wong JR, Berg CE, Kramer D. Endothelin stimulates glucose uptake via activation of endothelin-A receptor in neonatal rat cardiomyocytes. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1): S179-83.
109. Dalmay F, Pesteil F, Allard J, Nisse-Durgeat S, Fernandez L, Fournier A, et al. Angiotensin IV decreases acute stroke mortality in the gerbil. Hypertension 2001; 14(4): 56A.
110. Haberl RL, Anneser F, Villringer A, Einhaupl KM. Angiotensin II induces endothelium-dependent vasodilation of rat cerebral arterioles. Am J Physiol 1990; 258(6 Pt 2): H1840-6.
111. Haberl RL, Decker-Hermann PJ, Hermann K. Effect of renin on brain arterioles and cerebral blood flow in rabbits. J Cereb Blood Flow Metab 1996; 16(4): 714-9.
112. Haberl RL, Decker PJ, Einhaupl KM. Angiotensin degradation products mediate endothelium-dependent dilation of rabbit brain arterioles. Circ Res 1991; 68(6): 1621-7.
113. Haberl RL. Role of angiotensin receptor subtypes in the response of rabbit brain arterioles to angiotensin. Stroke 1994; 25(7): 1476-9.
114. Maktabi MA, Todd MM, Stachovic G. Angiotensin II contributes to cerebral vasodilatation during hypoxia in the rabbit. Stroke 1995; 26(10): 1871-6.
115. Walther T, Olah L, Harms C, Maul B, Bader M, Hortnagl H, et al. Ischaemic injury in experimental stroke depends on angiotensin II. FASEB J 2002; 16(2): 169-76.
116. Mies G, Olah L, Walther T. Angiotensin II AT2 receptor deletion increases ischaemic injury in experimental stroke. Stroke 2004; 35: 235.
117. Iwai M, Liu H, Chen R, et al. Important role of angiotensin II type 2 receptor in focal cerebral ischaemia induced by middle cerebral artery occlusion: study using receptor gene deficient mice. J Hypertens 2004; 22 (suppl 1): S9.
118. Dai W, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischaemia in rats. Stroke 1999; 30: 2391-2399.
119. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Blume A, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; [Epub ahead of print].
120. Gohlke P, Kox T, Jurgensen T, von Kugelgen S, Rascher W, Unger T, et al. Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats. Naunyn Schmiedebergs Arch Pharmacol 2002; 365(6): 477-83.
121. Groth W, Blume A, Gohlke P, Unger T, Colman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003; 21(11): 2175-2182.
122. Fournier A, Achard JM. Clinical relevance of the AT2-receptor mediated brain antiischaemic mechanisms evidenced by primary and secondary stroke prevention trials in patients. J Hypertens 2004; XXII supplt 1: 85S (abstract 290).
123. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35(3): 776-85. [Epub 2004 Feb 19].
124. MRC trial of treatment of mild hypertension: principal results.Medical Research Council Workiug Party. Br Med J (Clin Res Ed) 1985; 291: 97-104.
125. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304: 405-12.
126. Psaty B, Smith N, Siscovick D, Furberg C. Health outcomes associated with antihypertensive therapies used as just live agents. A systematic review and metaanalysis. JAMA 1997; 277: 739-745.
127. Brown MJ, Brown J. Does angiotensin II protect against strokes? Lancet 1986; 2 (8504): 427-429.
128. Hanson L, Lindholm L, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
129. PROGRESS collaborative group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
130. PATS collaborating group. Post-stroke Antihypertensive Study. Chinese Med J 1995; 108: 710-717.
131. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of angiotensin - converting-enzyme inhibitor on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. New Eng J Med 2000; 342: 145-153.
132. Klungel OH, Heckbert SR, Longstreth WT Jr, Furberg CD, Kaplan RC, Smith NL, et al. Antihypertensive drug therapies and the risk of ischaemic stroke. Arch Intern Med 2001; 161(1): 37-43.
133. Howard G, Howard VJ, Katholi C, Oli MK, Huston S. Decline in US stroke mortality: an analysis of temporal patterns by sex, race and geographic region. Stroke 2001; 32(10): 2213-20.
134. Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke 2001; 31: 1588-1601.
135. Lenfant C, Roccella EJ. A call to action for more aggressive treatment of hypertension. J Hypertens Suppl 1999; 17(1): S3-7.
136. Cooper R, Cutler J, Desvigne-Nickens P, Fortmann SP, Friedman L, Havlik R, et al. Trends and disparities in coronary heart disease, stroke and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000; 102(25): 3137-47.
137. Fournier A, Oprisiu R, Mazouz H. Stroke death rate annual decrease reversal and prescription decrease of antihypertensine drugs stimulating angiotensin II formation. Am J Hypertens 2002; 15: 106A.
138. Dahlöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
139. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34(7): 1699-703.
140. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003. (published online Sept1); 362: 759-66.
141. Fournier A, Oprisiu R andrejak M, Godefroy O, Rosa A, Achard JM. Age-adjusted stroke incidence increase: could angiotensin AT1 receptor antagonists enhance stroke prevention? Stroke 2002; 33(3): 881-2.
142. Brunner HR, Gavras H. Angiotensin blockade for hypertension: a promise fulfilled - commentary. Lancet 2002; 359(9311): 990-2.
143. Behnia R, Molteni A, Igic R. Angiotensin-converting enzyme inhibitors: mechanisms of action and implications in anesthesia practice. Curr Pharm Design 2003; 9(9): 763-76.
144. Marshall RP. The pulmonary renin-angiotensin system. Curr Pharm Design 2003; 9(9): 715-22.
145. Wilkinson-Berka JL, Fletcher EL. Angiotensin and bradykinin: targets for the treatment of vascular and neuro-glial pathology in diabetic retinopathy. Curr Pharm Design 2004; 10(27): 3313-30.